• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Therapeutic advances in cardiovascular disease. >The effect of angiotensin-converting enzyme inhibitors on clinical outcomes in patients with ischemic cardiomyopathy and midrange ejection fraction: a post hoc subgroup analysis from the PEACE trial
【24h】

The effect of angiotensin-converting enzyme inhibitors on clinical outcomes in patients with ischemic cardiomyopathy and midrange ejection fraction: a post hoc subgroup analysis from the PEACE trial

机译：血管紧张素转换酶抑制剂对缺血性心肌病和中程射血分数的患者临床结局的影响：PEACE试验的事后亚组分析

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

There have been significant advances in the treatment of patients with cardiomyopathy with reduced ejection fraction (EF post hoc subgroup analysis of the PEACE trial was conducted to evaluate the effect of ACE inhibitors in a subgroup of patients with ischemic cardiomyopathy and midrange EF (40–50%). A Chi-square test and a Student‘s t-test were used to examine and compare the binary and continuous variables of baseline characteristics and outcomes between experimental and comparison groups. We studied a subgroup of patients from the PEACE trial with ischemic cardiomyopathy and midrange EF (n = 2512 of 8290 total patients). Patients were assigned to either the interventional group (n = 1247) or the placebo group (n = 1265). There were no significant differences in baseline demographic and health characteristics between the two groups. During a total of 7 years (mean 4.7 years) of follow up, the risk of composite outcomes [all-cause mortality, nonfatal myocardial infarction, and stroke; relative risk (RR) 0.79, 95% confidence interval (CI) 0.63–0.98; p = 0.03] and all-cause mortality (RR 0.85, 95% CI 0.73–0.99; p = 0.03) was reduced in patients treated with trandolapril. This study revealed the benefit of ACE inhibitors among patients with ischemic cardiomyopathy and midrange EF.
机译：射血分数降低的心肌病患者的治疗取得了重大进展（对PEACE试验进行EF事后亚组分析，以评估ACE抑制剂对缺血性心肌病和中度EF患者亚组的作用（40–50 ％）。卡方检验和学生t检验用于检查和比较实验组和比较组之间基线特征和结局的二元和连续变量，我们研究了PEACE试验中局部缺血的患者亚组心肌病和中度EF（总共8290名患者中的2512名），将患者分为干预组（n = 1247）或安慰剂组（n = 1265），两组之间的基线人口统计学和健康特征无显着差异两组，在总共7年（平均4.7年）的随访中，复合结果的风险[全因死亡率，非致命性心肌梗塞和中风;相对风险（RR）0.79，95％置信区间（CI）0.63-0.98; p = 0.03]和trandolapril治疗的患者降低了全因死亡率（RR 0.85，95％CI 0.73–0.99; p = 0.03）。这项研究揭示了ACE抑制剂在缺血性心肌病和中度EF患者中的益处。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号